Edmonton, AB - CV Technologies Inc. (TSX-VEN:CVQ), an Alberta-based developer of natural health products, has appointed new members of the Board of Directors and management to strengthen the corporation and facilitate its intention to move from a research-based company to a fully commercialized corporation.
Mr. Andrew Osis has been appointed to the role of Chief Financial Officer (CFO) and brings eight years experience in the capital markets to CV Technologies. As a former Vice President, Global Banking for RBC Dominion Securities, Mr. Osis has in-depth knowledge of mergers, acquisitions and financial strategy.
Mr. Norman Oliver brings over 19 years experience in corporate outsourcing, sales, marketing, and consumer packaged goods with top tiered national brands to CV Technologies. Mr. Oliver as Senior Vice President Sales & Marketing will assist CV Technologies to develop a sales and distribution strategy towards profitable growth.
New Board of Directors appointments include: Mr. Hunter Wight, the Executive Director of Public Affairs and Development at Mount Royal College and Ms. Kit Chan, Principal of KBC Enterprises and Director of the Bank of Canada. They join CV Technologies' existing board members: Mr. Gordon Tallman, Mr. Bruce Buchanan, Dr. Robert Church and Dr. Jacqueline Shan.
Founder and President of this million-dollar company, Dr. Jacqueline Shan says, "These appointments strengthen our management team. Their efforts combined with those of the other five members of our company, will enable CV Technologies to fulfill our strategies of further enhancing consumer awareness of our cold-and-flu formulation and immune nutrient, Cold-FX(R); by developing globally recognized brands, expanding Canadian penetration and fostering new strategic initiatives to penetrate Europe and Asia."
About CV Technologies Inc.
CV Technologies, founded in 1992, aims to become a global leader in the development, distribution, marketing and selling of safe and effective natural health products for disease prevention and health maintenance.
CV's products are unique because they are developed and standardized according to the company's ChemBioPrint(TM) technology, a patented process that precisely identifies the chemical profile and biological activity of natural health products. This as a combination of chemical and pharmacological fingerprinting that ensures each batch of product delivers verifiable and provable health benefits, and is both safe and consistent with previous batches.
CV is a public company trading on the TSX Venture Exchange under the symbol CVQ.
This news release contains forward-looking statements that involve risks and uncertainties, which may cause actual results to differ materially from the statements made. For this purpose, any statements that are contained herein that are not statements of historical fact may be deemed to be forward-looking statements. Without limiting the foregoing, the words "believes", "anticipates", "plans", "intends", "expects" and similar expressions are intended to identify forward-looking statements. Such risks and uncertainties include, but are not limited to, the need for capital, changing market conditions, completion of clinical trials, patient enrolment rates, uncertainty of pre-clinical, retrospective and early clinical trial results, the establishment of manufacturing processes and new corporate alliances, the timely development, regulatory approval and market acceptance of the Company's products, and other risks detailed from time to time in the Company's filings with Canadian securities authorities.